Stay updated on Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A new 'Last Update Posted (Estimated)' field was added and the revision label updated to 'v3.3.4', replacing the previous 'Last Update Posted' field and 'Revision: v3.3.3'.
    Difference
    0.1%
    Check dated 2026-01-15T02:42:48.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The Locations section was updated to show 11 locations, and the Miami Cancer Institute site was removed from the list.
    Difference
    0.4%
    Check dated 2026-01-08T01:37:33.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    Study Record Dates show additions of newer date entries (e.g., 2025-12-31 and 2025-12-29) and removals of earlier timestamps (e.g., 2025-09-09 and 2025-09-08).
    Difference
    0.3%
    Check dated 2025-12-31T17:55:26.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The study Locations section now lists Connecticut, Florida, Indiana, New Jersey, New York, Pennsylvania, and Vermont as sites. A new revision note v3.3.3 appears on the page, and the HHS Vulnerability Disclosure footer link has been removed.
    Difference
    0.8%
    Check dated 2025-12-24T14:40:07.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The update shows a minor revision from v3.3.1 to v3.3.2. No substantive study content or user-facing features appear to be affected.
    Difference
    0.0%
    Check dated 2025-12-01T17:31:08.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    A new page revision label was added (v3.3.1) replacing the previous v3.2.0. There is no evident change to the study details, eligibility criteria, or outcomes in the visible content.
    Difference
    0.0%
    Check dated 2025-11-24T14:39:37.000Z thumbnail image

Stay in the know with updates to Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.